

CITATION REPORT

List of articles citing

Efficacy of low-dose spironolactone in subjects with resistant hypertension

DOI: 10.1016/s0895-7061(03)01032-x
American Journal of Hypertension, 2003, 16, 925-30.

Source: <https://exaly.com/paper-pdf/35557566/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
407	Evolution of diagnostic criteria for primary aldosteronism: why is it more common in "drug-resistant" hypertension today?. 2004 , 6, 485-92		18
406	No es necesario el despistaje del hiperaldosteronismo primario en la gran mayoría de los pacientes hipertensos. 2004 , 21, 114-118		
405	Commentary 2. 2004 , 8, 20-21		
404	Use of aldosterone antagonists in resistant hypertension. 2004 , 6, 458-60		10
403	Resistant hypertension, obesity, sleep apnea, and aldosterone: theory and therapy. 2004 , 43, 518-24		214
402	Primary aldosteronism: evolving concepts in diagnosis and treatment. 2004 , 11, 153-157		3
401	The current epidemic of primary aldosteronism: causes and consequences. 2004 , 22, 863-9		103
400	Primary hyperaldosteronism: a frequent cause of residual hypertension after successful endovascular treatment of renal artery disease. 2005 , 23, 2041-7		8
399	Changes in the usage of antihypertensive drugs: implications and prospects. 2005 , 60, 231-4		4
398	Primary aldosteronism: diagnostic and therapeutic considerations. 2005 , 7, 412-7		6
397	The risks and benefits of aldosterone antagonists. 2005 , 2, 65-71		15
396	Aldosterone antagonism: an emerging strategy for effective blood pressure lowering. 2005 , 7, 186-92		9
395	Treatment of resistant hypertension. 2005 , 7, 323-9		23
394	The role of aldosterone antagonists in the management of resistant hypertension. 2005 , 7, 343-7		28
393	Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis. 2005 , 10, 23-9		135
392	Improvement in blood pressure with inhibition of the epithelial sodium channel in blacks with hypertension. 2005 , 46, 481-7		137
391	Central role for ENaC in development of hypertension. 2005 , 16, 3154-9		76

390	Hyperaldosteronism and hypertension: ethnic differences. 2005 , 45, 766-72	77
389	Benefits of Diuretic-Based Low-Cost Antihypertensive Therapy. 2005 , 12, 73-78	
388	The aldosterone antagonist and facultative diuretic eplerenone: a critical review. 2005 , 16, 3-11	20
387	The aldosterone antagonist and facultative diuretic eplerenone: A critical review. 2005 , 16, 145-153	
386	Clinical pharmacology of antihypertensive therapy. 2005 , 25, 215-26	6
385	Aldosterone antagonists: effective add-on therapy for the treatment of resistant hypertension. 2006 , 4, 353-9	8
384	Hipertensi arterial refractaria. 2006 , 23, 184-194	
383	Resistant or difficult-to-treat hypertension. 2006 , 8, 181-6	20
382	Hipertensi arterial refractaria. 2006 , 23, 184-194	
381	Antihypertensive therapy and its effects on potassium homeostasis. 2006 , 8, 67-73	27
380	Spirolactone: an old friend rediscovered. 2006 , 8, 467-9	2
379	Primary aldosteronism: diagnosis and treatment. 2006 , 8, 887-93	23
378	Can the dextroenantiomer of the aromatase inhibitor fadrozole be useful for clinical investigation of aldosterone-synthase inhibition?. 2006 , 24, 993-7	25
377	Characteristics of resistant hypertension determined by self-measured blood pressure at home and office blood pressure measurements: the J-HOME study. 2006 , 24, 1737-43	61
376	Japanese Society of Hypertension. 2006 , 29, S1-S105	29
375	Does eplerenone have a future in the management of hypertension in Europe?. 2006 , 20, 829-32	4
374	Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy. 2006 , 70, 536-42	145
373	[Modern pharmacological aspects of hyperaldosteronism therapy]. 2006 , 47, 953-9	3

372	Use of aldosterone antagonists in resistant hypertension. 2006 , 48, 387-96	47
371	Adrenal corticosteroids, their receptors and hypertension. 2006 , 67, 871-883	5
370	Resistant hypertension: diagnosis and management. 2006 , 11, 113-8	24
369	Mechanisms of sympathetic activation in obesity-related hypertension. 2006 , 48, 787-96	315
368	Hypertension in the metabolic syndrome. 2006 , 4, 287-98	12
367	Evaluation of the aldosterone-blocking agent eplerenone in hypertension and heart failure. 2007 , 8, 3053-9	12
366	Response to Interleukin-6 Antagonists for the Management of Hypertension. 2007 , 49,	
365	Hypertension. 2007 ,	
364	Non-steroidal mineralocorticoid receptor antagonists. 2007 , 17, 17-23	15
363	Is there an unrecognized epidemic of primary aldosteronism? Pro. 2007 , 50, 447-53; discussion 447-53	74
362	Will the lessons from primary aldosteronism change the treatment of hypertension and left ventricular hypertrophy?. 2007 , 50, 837-9	1
361	Effect of spironolactone on blood pressure in subjects with resistant hypertension. 2007 , 49, 839-45	495
360	The spironolactone, amiloride, losartan, and thiazide (SALT) double-blind crossover trial in patients with low-renin hypertension and elevated aldosterone-renin ratio. 2007 , 116, 268-75	76
359	Aldosterone and refractory hypertension. 2007 , 14, 213-8	4
358	Hyperaldosteronism: a commonly occurring underlying feature of essential hypertension and the metabolic syndrome?. 2007 , 14, 210-2	1
357	Low-dose spironolactone in the management of resistant hypertension: a surveillance study. 2007 , 25, 891-4	96
356	Aldosterone, mineralocorticoid receptors, and vascular inflammation. 2007 , 16, 134-42	11
355	Aldosterone excess and resistance to 24-h blood pressure control. 2007 , 25, 2131-7	29

354	Aldosterone antagonist therapy in resistant hypertension. 2007 , 25, 747-50	24
353	Resistant hypertension and aldosterone excess: new insights from ambulatory blood pressure monitoring. 2007 , 25, 2006-7	1
352	Resistant hypertension: prevalence and evolving concepts. 2007 , 9, 2-6	29
351	Low-dose aldosterone blockade as a new treatment paradigm for controlling resistant hypertension. 2007 , 9, 19-24	24
350	Historical perspective of low- vs. high-dose diuretics. 2007 , 1, 373-80	5
349	The association of aldosterone with obesity-related hypertension and the metabolic syndrome. 2007 , 27, 529-37	35
348	Drospirenone for oral contraception and hormone replacement therapy: are its cardiovascular risks and benefits the same as other progestogens?. 2007 , 67, 647-55	11
347	Pathophysiology of Obesity-Induced Hypertension and Target Organ Damage. 2007 , 447-468	11
346	Pathophysiology of Hypertension. 2007 , 25-46	3
345	Diuretic Therapy in Cardiovascular Disease. 2007 , 213-230	2
344	Diuretics. 2007 , 949-957	
343	Diagnosis and treatment of low-renin hypertension. 2007 , 67, 324-34	70
342	Maximizing diuretic therapy in resistant hypertension. 2007 , 9, 802-6	4
341	Good blood pressure control on antihypertensives, not only response to spironolactone, predicts improved outcome after adrenalectomy for aldosteronoma. 2007 , 142, 921-9; discussion 921-9	29
340	Primary aldosteronism. 2007 , 9, 447-52	2
339	The role of aldosterone in resistant hypertension: implications for pathogenesis and therapy. 2007 , 9, 98-105	14
338	Spironolactone use in resistant hypertension. 2007 , 9, 297-8	3
337	Resistant hypertension and aldosteronism. 2007 , 9, 353-9	40

336	Treating resistant hypertension with spironolactone. 2008 , 10, 211-2	
335	Obesity, sleep apnea, aldosterone, and hypertension. 2008 , 10, 222-6	32
334	Resistant hypertension and hyperaldosteronism. 2008 , 10, 496-503	26
333	Diagnostic evaluation of plasma aldosterone concentration to plasma renin activity ratio in primary aldosteronism. 2008 , 2, 11-14	
332	A comparison of the aldosterone-blocking agents eplerenone and spironolactone. 2008 , 31, 153-8	149
331 ¹	ASH position paper: treatment of hypertension in patients with diabetes-an update. 2008 , 10, 707-13; discussion 714-5	43
330	Well tolerated spironolactone-related hyponatremia. 2008 , 10, 317-21	10
329	Drug Insight: eplerenone, a mineralocorticoid-receptor antagonist. 2008 , 4, 44-52	21
328	[Spironolactone in patients with resistant hypertension]. 2008 , 131, 406-11	5
327	Pathophysiology of Primary Hypertension. 2008 , 794-895	1
326	Resistant hypertension: an overview of evaluation and treatment. 2008 , 52, 1749-57	253
325	Effectiveness of the selective aldosterone blocker, eplerenone, in patients with resistant hypertension. 2008 , 2, 462-8	91
324	Management of hypertension in the outpatient setting. 2008 , 35, 451-73, vi	3
323	Is Renin-Based Treatment a Reasonable Strategy to Treat Essential Hypertension?. 2008 , 15, 121-125	1
322	Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. 2008 , 51, 1403-19	1136
321	Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion. 2008 , 168, 1159-64	197
320	Pathophysiology of Primary Hypertension. 2008 , 794-895	3
319	Race-based therapy for hypertension: possible benefits and potential pitfalls. 2008 , 6, 1357-66	24

318	A not-so-modest proposal that a "modest" increase in aldosterone causes hypertension and more. 2008 , 51, 39-40		5
317	The Impact of Continuous Positive Airway Pressure on Blood Pressure in Patients with Obstructive Sleep Apnea Syndrome: Evidence From a Meta-analysis of Placebo-Controlled Randomized Trials. 2008 , 2008, 88-89		
316	Effect of Spironolactone on Blood Pressure in Subjects With Resistant Hypertension. 2008 , 2008, 37-39		
315	Effect of Nocturnal Nasal Continuous Positive Airway Pressure on Blood Pressure in Obstructive Sleep Apnea. 2008 , 2008, 89-91		
314	Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. 2008 , 117, e510-26		895
313	Resistant hypertension: identifying causes and optimizing treatment regimens. 2008 , 101, 166-73		14
312	The Impact of Continuous Positive Airway Pressure on Blood Pressure in Patients with Obstructive Sleep Apnea Syndrome: Evidence From a Meta-analysis of Placebo-Controlled Randomized Trials. 2008 , 2008, 352-353		
311	Treatment resistant hypertension. 2008 , 15, 351-5		2
310	Clinical approach in treatment of resistant hypertension. 2009 , 2, 9-23		3
309	Aldosterone in clinical nephrology--old hormone, new questions. 2009 , 24, 2316-21		7
308	Use of single-pill combination therapy in the evolving paradigm of hypertension management. 2009 , 10, 1869-74		10
307	Differential effects of chlorthalidone versus spironolactone on muscle sympathetic nerve activity in hypertensive patients. 2009 , 94, 1361-6		59
306	Plasma Renin test-guided drug treatment algorithm for correcting patients with treated but uncontrolled hypertension: a randomized controlled trial. <i>American Journal of Hypertension</i> , 2009 , 22, 792-801	2,3	102
305	Spironolactone and chlorthalidone in uncontrolled elderly hypertensive patients treated with calcium antagonists and angiotensin II receptor-blocker: effects on endothelial function, inflammation, and oxidative stress. 2009 , 31, 585-94		18
304	Sleep apnea, aldosterone, and resistant hypertension. 2009 , 51, 371-80		53
303	Fixed-dosed combinations are not indicated as initial therapy: a debate. 2009 , 11, 94-9		0
302	Aldosterone excess or escape: Treating resistant hypertension. 2009 , 11, 245-52		21
301	Aldosterone and cardiovascular disease. 2009 , 34, 51-84		38

300	Characterization and treatment of resistant hypertension. 2009 , 11, 407-13	28
299	Spironolactone and doxazosin treatment in patients with resistant hypertension. 2009 , 62, 158-66	11
298	Physiology and Regulation of the Renin-Angiotensin-Aldosterone System. 2009 , 147-165	
297	Use of diuretics in patients with hypertension. 2009 , 361, 2153-64	159
296	Reduction of blood pressure in patients with treatment-resistant hypertension. 2009 , 10, 2959-71	3
295	Current options for the treatment of resistant hypertension. 2009 , 7, 1385-93	4
294	Treatment of hypertension in patients with diabetes-an update. 2009 , 3, 150-5	10
293	Interventional management of resistant hypertension. 2009 , 373, 1228-30	24
292	A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial. 2009 , 374, 1423-31	222
291	Uso de espironolactona o doxazosina en pacientes con hipertensi3n arterial refractaria. 2009 , 62, 158-166	32
290	Comparison of effects of low dose of spironolactone and a thiazide diuretic in patients with hypertension treated with an angiotensin-converting enzyme inhibitor or an angiotensin type 1 receptor blocker. 2009 , 31, 648-56	6
289	Hypertension and cardiac failure in its various forms. 2009 , 93, 665-80	23
288	Aldosterone-receptor antagonism in hypertension. 2009 , 27, 680-91	66
287	Resistant hypertension: who and how to evaluate. 2009 , 24, 340-4	4
286	Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study. 2009 , 2009, 113-115	
285	New therapeutic options in patients prone to hypertension: a focus on direct Renin inhibition and aldosterone blockade. 2009 , 337, 438-44	14
284	Spironolactone for hypertension. 2010 , CD008169	29
283	Management of resistant arterial hypertension: role of spironolactone versus double blockade of the renin-angiotensin-aldosterone system. 2010 , 28, 2329-35	59

282	Dual blockade of the renin-angiotensin-aldosterone system in cardiac and renal disease. 2010 , 19, 140-52	23
281	Hypertension: spironolactone and resistant hypertension. 2010 , 6, 248-50	3
280	Have the renin-angiotensin-aldosterone system perturbations in cardiovascular disease been exhausted?. 2010 , 12, 450-63	7
279	Renal nerves in the maintenance of hypertension: a potential therapeutic target. 2010 , 12, 196-204	19
278	The Role of Aldosterone Blockade in Patients with Hypertensive Heart and Cardiovascular Disease. 2010 , 2, CMT.S2232	
277	Management of high blood pressure in Blacks: an update of the International Society on Hypertension in Blacks consensus statement. 2010 , 56, 780-800	327
276	Aldosterone: role in edematous disorders, hypertension, chronic renal failure, and metabolic syndrome. 2010 , 5, 1132-40	74
275	Efficacy of spironolactone therapy in patients with true resistant hypertension. 2010 , 55, 147-52	189
274	Understanding the risk of hyperkalaemia in heart failure: role of aldosterone antagonism. 2010 , 86, 136-42	19
273	Relationship between overnight rostral fluid shift and obstructive sleep apnea in drug-resistant hypertension. 2010 , 56, 1077-82	155
272	Aldosterone receptor antagonists: effective but often forgotten. 2010 , 121, 934-9	65
271	Divergent results using clinic and ambulatory blood pressures: report of a darusentan-resistant hypertension trial. 2010 , 56, 824-30	141
270	Clinical effects of eplerenone, a selective aldosterone blocker, in Japanese patients with essential hypertension. 2010 , 24, 387-94	24
269	Treatment of resistant hypertension. 2010 , 28, 2194-5	12
268	Challenging hypertension: how to diagnose and treat resistant hypertension in daily clinical practice. 2010 , 8, 811-20	16
267	The role of aldosteronism in causing obesity-related cardiovascular risk. 2010 , 28, 517-27	53
266	Papel de la MAPA en el manejo de la hipertensi3n arterial resistente. 2010 , 27, 34-40	
265	Diuretics in clinical practice. Part I: mechanisms of action, pharmacological effects and clinical indications of diuretic compounds. 2010 , 9, 243-57	29

264	Diuretics in clinical practice. Part II: electrolyte and acid-base disorders complicating diuretic therapy. 2010 , 9, 259-73	30
263	Aldosterone and arterial hypertension. 2010 , 6, 83-93	93
262	Spironolactone management of resistant hypertension. 2010 , 44, 1762-9	25
261	Treatment of hypertension in patients with diabetes--an update. 2010 , 4, 62-7	11
260	Spironolactone for difficult to control hypertension in chronic kidney disease: an analysis of safety and efficacy. 2010 , 4, 295-301	19
259	The effect of low-dose spironolactone on resistant hypertension. 2010 , 4, 290-4	55
258	Resistant hypertension, secondary hypertension, and hypertensive crises: diagnostic evaluation and treatment. 2010 , 28, 639-54	46
257	Trends in 24-h urinary sodium excretion in the United States, 1957-2003: a systematic review. 2010 , 92, 1172-80	118
256	Therapy of hypertension in African Americans. 2011 , 11, 83-92	22
255	Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial. 2011 , 57, 1069-75	241
254	INCREASE IN TREATMENT-REFRACTORY HYPERTENSION: PROGRESS IN CURRENT TREATMENT BY PRIMARY CARE. 2011 , 28, 196-203	
253	Diuretics in the treatment of hypertension. 2011 , 31, 495-502	4
252	Mineralocorticoid receptor antagonists for heart failure. 2011 , 12, 2767-9	3
251	Long-term use of aldosterone-receptor antagonists in uncontrolled hypertension: a retrospective analysis. 2011 , 2011, 368140	4
250	Benefits from treatment and control of patients with resistant hypertension. 2010 , 2011, 318549	12
249	Pathophysiology of resistant hypertension: the role of sympathetic nervous system. 2011 , 2011, 642416	83
248	Role of the kidneys in resistant hypertension. 2011 , 2011, 143471	30
247	Resistant hypertension workup and approach to treatment. 2010 , 2011, 598694	11

246	Common secondary causes of resistant hypertension and rational for treatment. 2011 , 2011, 236239	49
245	Aldosteronism and resistant hypertension. 2011 , 2011, 837817	23
244	A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism. 2011 , 29, 980-90	151
243	Efficacy of Spironolactone Therapy in Patients With True Resistant Hypertension. 2011 , 2011, 86-88	
242	Continuous positive airway pressure treatment in sleep apnea patients with resistant hypertension: a randomized, controlled trial. 2011 , 2011, 379-380	
241	Continuous positive airway pressure treatment in sleep apnea patients with resistant hypertension: a randomized, controlled trial. 2011 , 2011, 84-86	
240	Potential benefits of quinoxaline 1, 4-dioxides in aldosterone dysmetabolism disease: a medical hypothesis. 2011 , 01, 121-127	1
239	Treatment considerations with aldosterone receptor antagonists. 2011 , 13, 65-9	10
238	Drug therapy for resistant hypertension: simplifying the approach. 2011 , 13, 120-30	29
237	Evidence-based diuretic therapy for improving cardiovascular prognosis in systemic hypertension. 2011 , 107, 1178-84	11
236	Management of hypertension in patients with coronary artery disease. 2011 , 9, 1271-7	4
235	Can catheter-based renal denervation be used safely and effectively to substantially reduce blood pressure in treatment-resistant hypertensive patients?. 2011 , 13, 478-80	1
234	Resistant hypertension: concepts and approach to management. 2011 , 13, 347-55	19
233	Cardiac dimensions are largely determined by dietary salt in patients with primary aldosteronism: results of a case-control study. 2011 , 96, 2813-20	56
232	Therapeutic perspectives in hypertension: novel means for renin-angiotensin-aldosterone system modulation and emerging device-based approaches. 2011 , 32, 2739-47	83
231	Prevalence of resistant hypertension in the United States, 2003-2008. 2011 , 57, 1076-80	558
230	Rationale for the use of multiple blockers of the renin-angiotensin-aldosterone system in specific patient populations. 2011 , 8, 227-236	2
229	Efficacy of eplerenone added to renin-angiotensin blockade in elderly hypertensive patients: the Jichi-Eplerenone Treatment (JET) study. 2011 , 12, 340-7	18

228	Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo- and active-controlled phase 2 trial. 2011 , 124, 1945-55		145
227	What is new in the management of resistant hypertension?. 2011 , 8, 261-273		2
226	Renal sympathetic denervation: renal function concerns. 2011 , 58, e19; author reply e20		24
225	Description of antihypertensive use in patients with resistant hypertension prescribed four or more agents. 2011 , 58, 1008-13		57
224	Low-dose and very low-dose spironolactone in combination therapy for essential hypertension: evaluation by self-measurement of blood pressure at home. 2011 , 33, 427-36		4
223	Strategies for combination therapy in hypertension. 2012 , 21, 486-91		17
222	Response to Letter to Regarding Article, Effects of Novel Aldosterone Synthase Inhibitor for Treatment of Primary Hypertension: Results of a Randomized, Double-Blind, Placebo- and Active-Controlled Phase 2 Trial 2012 , 125,		
221	Evaluation and pharmacologic approach to patients with resistant hypertension. 2012 , 124, 74-82		3
220	Recent advancements in the treatment of resistant hypertension. 2012 , 124, 67-73		6
219	Mineralocorticoid receptor-associated hypertension and its organ damage: clinical relevance for resistant hypertension. <i>American Journal of Hypertension</i> , 2012 , 25, 514-23	2,3	68
218	Long-term effects of aldosterone blockade in resistant hypertension associated with chronic kidney disease. 2012 , 26, 502-6		37
217	Eplerenone, an aldosterone blocker, is more effective in reducing blood pressure in patients with, than without, metabolic syndrome. 2012 , 6, 141-7		5
216	Hypertension in the elderly. 2012 , 4, 135-47		112
215	Low-dose spironolactone prevents apoptosis repressor with caspase recruitment domain degradation during myocardial infarction. 2012 , 59, 1164-9		34
214	Overlapping spironolactone dosing in primary aldosteronism and resistant essential hypertension. 2012 , 14, 732-4		6
213	Variations in the potassium channel genes KCNK3 and KCNK9 in relation to blood pressure and aldosterone production: an exploratory study. 2012 , 97, E2160-7		18
212	[Treatment resistant hypertension. Value of a new treatment concept]. 2012 , 53, 1411-9		1
211	Resistant hypertension, obstructive sleep apnoea and aldosterone. 2012 , 26, 281-7		101

210	Resistant hypertension and aldosterone: an update. 2012 , 28, 318-25	41
209	Evaluation of the ASPIRANT trial. 2012 , 13, 2573-7	1
208	Safety of mineralocorticoid receptor antagonists in patients receiving hemodialysis. 2012 , 46, 889-94	22
207	Novel Pharmacological Approaches in Hypertension Treatment. 2012 , 175-184	
206	Key advances in antihypertensive treatment. 2012 , 9, 276-85	39
205	Spironolactone treatment in patients with diabetic microalbuminuria and resistant hypertension. 2012 , 32, 33-36	5
204	Aldosterone in heart disease. 2012 , 14, 125-9	14
203	A simplified mechanistic algorithm for treating resistant hypertension: efficacy in a retrospective study. 2012 , 14, 191-7	15
202	New prescriptions of spironolactone associated with angiotensin-converting-enzyme inhibitors and/or angiotensin receptor blockers and their laboratory monitoring from 2001 to 2008: a population study on older people living in the community in Italy. 2013 , 69, 909-17	4
201	Salt, the renin-angiotensin-aldosterone system and resistant hypertension. 2013 , 36, 657-60	25
200	Individualization of antihypertensive drug treatment. 2013 , 36 Suppl 2, S301-6	8
199	Pathogenesis of Hypertension. 2013 , 12-26	3
198	Resistant hypertension. 2013 , 213, 388-393	
197	International expert consensus statement: Percutaneous transluminal renal denervation for the treatment of resistant hypertension. 2013 , 62, 2031-45	104
196	Mineralocorticoid receptor antagonists: their use and differentiation in Japan. 2013 , 36, 185-90	13
195	Renal denervation in a patient with two renal accessory arteries: a case report. 2013 , 22, 325-8	
194	Treatment of hypertension in obese patients. 2013 , 13, 163-75	8
193	Salt, aldosterone and hypertension. 2013 , 27, 1-6	20

192 Resistant Hypertension. **2013**, 501-509

191 Hyperaldosteronism as a common cause of resistant hypertension. **2013**, 64, 233-47

70

190 Diuretic Therapy in Cardiovascular Disease. **2013**, 160-171

189 Resistant hypertension. **2013**, 213, 388-93

2

188 Endocrine and hypertensive disorders of potassium regulation: primary aldosteronism. **2013**, 33, 265-76

15

187 Hypertensive Emergencies and Resistant Hypertension. **2013**, 533-544

1

186 Epidemiology, prognosis, and treatment of resistant hypertension. **2013**, 33, 1071-86

10

185 Resistant Hypertension. **2013**, 7, 354-363

1

184 Proposal of a new strategy for ambulatory blood pressure profile-based management of resistant hypertension in the era of renal denervation. **2013**, 36, 478-84

50

183 Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. **2013**, 34, 2453-63

282

182 Renal denervation in the management of resistant hypertension: current evidence and perspectives. **2013**, 22, 511-8

5

181 Resistant hypertension. **2013**, 252-269

180 Diuretic use in black patients with uncontrolled hypertension. *American Journal of Hypertension*, **2013**, 26, 174-9

2.3 6

179 Improved blood pressure control in the hands of the hypertension specialist: method, magic, or something in between?. **2013**, 15, 615-6

178 Prevalence of apparent treatment-resistant hypertension among individuals with CKD. **2013**, 8, 1583-90

103

177 Prevalence and clinical characteristics of primary aldosteronism in Japanese patients with type 2 diabetes mellitus and hypertension. **2013**, 60, 967-76

17

176 Spironolactone, eplerenone and the new aldosterone blockers in endocrine and primary hypertension. **2013**, 31, 3-15

73

175 Determinants of blood pressure reduction by eplerenone in uncontrolled hypertension. **2013**, 31, 404-13

17

174	Management of patients with resistant hypertension: current treatment options. 2013 , 6, 139-51	20
173	Mineralocorticoid receptor antagonists: emerging roles in cardiovascular medicine. 2013 , 6, 129-38	63
172	Aldosterone receptor antagonists: current perspectives and therapies. 2013 , 9, 321-31	25
171	Non-interventional management of resistant hypertension. 2014 , 6, 1080-90	4
170	Resistant hypertension and untreated severe sleep apnea: slowly gaining insight. 2014 , 10, 845-6	3
169	Chapter 5. Treatment with antihypertensive drugs. 2014 , 37, 291-300	2
168	Role of sodium restriction and diuretic therapy for "resistant" hypertension in chronic kidney disease. 2014 , 34, 514-9	6
167	Serum potassium levels predict blood pressure response to aldosterone antagonists in resistant hypertension. 2014 , 37, 1037-41	9
166	Sympathetic activation in resistant hypertension: theory and therapy. 2014 , 34, 550-9	11
165	Ambulatory blood pressure and adherence monitoring: diagnosing pseudo-resistant hypertension. 2014 , 34, 498-505	11
164	Pathophysiology and treatment of resistant hypertension: the role of aldosterone and amiloride-sensitive sodium channels. 2014 , 34, 532-9	10
163	Is there a new dawn for selective mineralocorticoid receptor antagonism?. 2014 , 23, 456-61	12
162	Blood pressure and neurohormonal responses to renal nerve ablation in treatment-resistant hypertension. 2014 , 32, 135-41	27
161	A critical review of the evidence supporting aldosterone in the etiology and its blockade in the treatment of obesity-associated hypertension. 2014 , 28, 3-9	18
160	Hipertensiã arterial resistente. 2014 , 31, 58-65	0
159	Physician underutilization of effective medications for resistant hypertension at office visits in the United States: NAMCS 2006-2010. 2014 , 29, 468-76	25
158	Are there any new pharmacologic therapies on the horizon to better treat hypertension? A state-of-the-art paper. 2014 , 19, 516-25	3
157	Converging indications of aldosterone antagonists (spironolactone and eplerenone): a narrative review of safety profiles. 2014 , 16, 414	24

156	An Update on Treatment Options for Drug Resistant Hypertension. 2014 , 8, 1	
155	Pathophysiology, diagnosis, and treatment of mineralocorticoid disorders. 2014 , 4, 1083-119	9
154	Apparent treatment-resistant hypertension and chronic kidney disease: another cardiovascular-renal syndrome?. 2014 , 21, 489-99	5
153	Renin-angiotensin-aldosterone system inhibition: overview of the therapeutic use of angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, mineralocorticoid receptor antagonists, and direct renin inhibitors. 2014 , 41, 765-78	18
152	Individualizing antihypertensive combination therapies: clinical and hemodynamic considerations. 2014 , 16, 451	8
151	Diuretics in the treatment of hypertension. Part 2: loop diuretics and potassium-sparing agents. 2014 , 15, 605-21	39
150	Proceedings from Duke resistant hypertension think tank. 2014 , 167, 775-88.e1	13
149	Mechanism of salt-sensitive hypertension: focus on adrenal and sympathetic nervous systems. 2014 , 25, 1148-55	81
148	Comparison of agents that affect aldosterone action. 2014 , 34, 285-306	23
147	Modulation of aldosterone levels by -344 C/T CYP11B2 polymorphism and spironolactone use in resistant hypertension. 2014 , 8, 146-51	18
146	Effect of spironolactone in resistant arterial hypertension: a randomized, double-blind, placebo-controlled trial (ASPIRANT-EXT). 2014 , 93, e162	36
145	Mineralocorticoid Receptor Antagonists for Treatment of Hypertension and Heart Failure. 2015 , 11, 235-9	18
144	References. 2015 , 123-134	
143	Mineralocorticoid Receptor Antagonists Therapy in Resistant Hypertension: Time to Implement Guidelines!. 2015 , 2, 3	5
142	Drug therapy for the patient with resistant hypertension. 2015 , 11, 191-202	1
141	Effect of aldosterone antagonists on blood pressure in patients with resistant hypertension: a meta-analysis. 2015 , 29, 159-66	26
140	Primary aldosteronism and salt. 2015 , 467, 587-94	21
139	New approaches in the treatment of hypertension. 2015 , 116, 1074-95	159

138	The Baroreflex in Hypertension. 2015 , 17, 19		13
137	Pharmacological treatment of aldosterone excess. 2015 , 154, 120-33		22
136	Genetics of resistant hypertension: a novel pharmacogenomics phenotype. 2015 , 17, 583		15
135	Natriuretic Peptides as a Novel Target in Resistant Hypertension. 2015 , 17, 18		4
134	The Effects of Aldosterone Antagonists in Patients With Resistant Hypertension: A Meta-Analysis of Randomized and Nonrandomized Studies. <i>American Journal of Hypertension</i> , 2015 , 28, 1376-85	2-3	71
133	Drug therapy of apparent treatment-resistant hypertension: focus on mineralocorticoid receptor antagonists. 2015 , 75, 473-85		12
132	Personalizing the diuretic treatment of hypertension: the need for more clinical and research attention. 2015 , 17, 542		2
131	Not just chlorthalidone: evidence-based, single tablet, diuretic alternatives to hydrochlorothiazide for hypertension. 2015 , 17, 540		7
130	Management of resistant hypertension: aldosterone antagonists or intensification of diuretic therapy?. 2015 , 20, 567-71		10
129	Mineralocorticoid exposure and receptor activity modulate microvascular endothelial function in African Americans with and without hypertension. 2015 , 20, 401-8		9
128	An Update on Inpatient Hypertension Management. 2015 , 17, 94		13
127	Prevention And Treatment of Hypertension With Algorithm-based therapy (PATHWAY) number 2: protocol for a randomised crossover trial to determine optimal treatment for drug-resistant hypertension. 2015 , 5, e008951		12
126	Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. 2015 , 386, 2059-2068		632
125	Primary Aldosteronism: unnecessary complexity in definition and diagnosis as a barrier to wider clinical care. 2015 , 82, 779-84		8
124	Mineralocorticoids in the heart and vasculature: new insights for old hormones. 2015 , 55, 289-312		34
123	Resistant hypertension: medical management and alternative therapies. 2015 , 33, 75-87		7
122	Use of Diuretics in Chronic Kidney Disease Patients. 2015 , 682-692		1
121	Urinary sodium excretion predicts blood pressure response to spironolactone in patients with resistant hypertension independent of aldosterone status. 2016 , 34, 1005-10		12

120	Predictors of blood pressure response to spironolactone. 2016 , 34, 845-7		0
119	Prevalence and characteristics of patients with resistant hypertension and chronic kidney disease. 2016 , 36, 523-529		4
118	Spironolactone versus sympathetic renal denervation to treat true resistant hypertension: results from the DENERVHTA study - a randomized controlled trial. 2016 , 34, 1863-71		50
117	Spironolactone versus renal nerve denervation for treatment of uncontrolled resistant hypertension. 2016 , 34, 1701-3		2
116	Guidelines for primary aldosteronism: uptake by primary care physicians in Europe. 2016 , 34, 2253-7		85
115	Efficacy and Safety of Spironolactone in Patients with Resistant Hypertension: A Meta-analysis of Randomised Controlled Trials. 2016 , 25, 1021-30		30
114	New Evidence Supporting the Use of Mineralocorticoid Receptor Blockers in Drug-Resistant Hypertension. 2016 , 18, 34		22
113	Effects of mineralocorticoid receptor antagonists in patients with hypertension and diabetes mellitus: a systematic review and meta-analysis. 2016 , 30, 534-42		22
112	Refractory Hypertension: A Novel Phenotype of Antihypertensive Treatment Failure. 2016 , 67, 1085-92		37
111	[Benefits of spironolactone as the optimal treatment for drug resistant hypertension. Pathway-2 trial review]. 2016 , 33, 150-154		2
110	Add-On Use of Eplerenone Is Effective for Lowering Home and Ambulatory Blood Pressure in Drug-Resistant Hypertension. 2016 , 18, 1250-1257		17
109	Prevalence and characteristics of patients with resistant hypertension and chronic kidney disease. 2016 , 36, 523-529		7
108	Small Potassium Channels: Speculation on a Role to Regulate Aldosterone Production and Blood Pressure. 2016 , 68, 542-3		
107	Body Mass Index Predicts 24-Hour Urinary Aldosterone Levels in Patients With Resistant Hypertension. 2016 , 68, 995-1003		31
106	Primary Aldosteronism: A Field on the Move. <i>Updates in Hypertension and Cardiovascular Protection</i> , 2016 , 29-55	0.1	1
105	Hypertension in Chronic Kidney Disease. 2017 , 956, 307-325		51
104	Diuretics prevent Rho-kinase activation and expression of profibrotic/oxidative genes in the hypertensive aortic wall. 2016 , 10, 338-347		5
103	Should All Patients with Resistant Hypertension Receive Spironolactone?. 2016 , 18, 81		6

102	Effect of low-dose spironolactone on resistant hypertension in type 2 diabetes mellitus: a randomized controlled trial in a sub-Saharan African population. 2016 , 9, 187		13
101	Drug Development for Hypertension: Do We Need Another Antihypertensive Agent for Resistant Hypertension?. 2016 , 18, 25		6
100	Resistant and Refractory Hypertension: Antihypertensive Treatment Resistance vs Treatment Failure. 2016 , 32, 603-6		30
99	Primary Mineralocorticoid Excess Disorders and Hypertension. 2016 , 1871-1891.e6		
98	Resistant Hypertension: An Update of Experimental and Clinical Findings. 2017 , 70, 5-9		30
97	Physiological Phenotyping for Personalized Therapy of Uncontrolled Hypertension in Africa. <i>American Journal of Hypertension</i> , 2017 , 30, 923-930	2.3	51
96	Management of Hypertension in Patients with Chronic Kidney Disease. 2017 , 19, 43		16
95	Salt-dependent Blood Pressure in Human Aldosterone Synthase-Transgenic Mice. 2017 , 7, 492		12
94	How does obesity affect the endocrine system? A narrative review. 2017 , 7, 136-144		23
93	Hypertension in African Americans. 2017 , 19, 129		33
92	Use of Aldosterone Antagonists for Treatment of Uncontrolled Resistant Hypertension. <i>American Journal of Hypertension</i> , 2017 , 30, 103-109	2.3	34
91	Managing resistant hypertension: focus on mineralocorticoid-receptor antagonists. 2017 , 13, 403-411		14
90	Spironolactone and Resistant Hypertension in Heart Failure With Preserved Ejection Fraction. <i>American Journal of Hypertension</i> , 2018 , 31, 407-414	2.3	20
89	Diagnosis and management of resistant hypertension: state of the art. 2018 , 14, 428-441		16
88	Pharmacotherapeutic strategies for treating hypertension in patients with obesity. 2018 , 19, 643-651		8
87	Mineralocorticoid Receptor in Calcium Handling of Vascular Smooth Muscle Cells. 2018 ,		1
86	Diagnosis, Prevention, and Treatment of Hypertensive Emergency/Hypertensive Crisis/Refractory Hypertension. 2018 , 263-288		
85	Patiromer to Enable Spironolactone Use in the Treatment of Patients with Resistant Hypertension and Chronic Kidney Disease: Rationale and Design of the AMBER Study. 2018 , 48, 172-180		17

84	Age-Related Blood Pressure Sensitivity to Aldosterone in Blacks and Whites. 2018 , 72, 247-252	16
83	Prevalence and Comorbidities of Resistant Hypertension: A Collaborative Population-Based Observational Study. 2018 , 25, 295-301	9
82	Physiology and Regulation of the Renin-Angiotensin-Aldosterone System. 2018 , 1-25	7
81	Aldosterone and Its Cardiovascular Effects. 2018 , 451-463	
80	Hypertension and Diabetes. 2018 , 1-22	
79	Renin Angiotensin Aldosterone System Blockers. 2018 , 230-241	1
78	The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019). 2019 , 42, 1235-1481	468
77	Resistant Hypertension Updated Guidelines. 2019 , 21, 117	10
76	Long-term phase 3 study of esaxerenone as mono or combination therapy with other antihypertensive drugs in patients with essential hypertension. 2019 , 42, 1932-1941	25
75	Efficacy and safety of dosage-escalation of low-dosage esaxerenone added to a RAS inhibitor in hypertensive patients with type 2 diabetes and albuminuria: a single-arm, open-label study. 2019 , 42, 1572-1581	19
74	Efficacy and safety of esaxerenone (CS-3150) for the treatment of essential hypertension: a phase 2 randomized, placebo-controlled, double-blind study. 2019 , 33, 542-551	24
73	Sex-specific responses to mineralocorticoid receptor antagonism in hypertensive African American males and females. 2019 , 10, 24	8
72	Resistant Hypertension: Diagnosis and Management. 2019 , 26, 99-109	4
71	Eplerenone Versus Spironolactone in Resistant Hypertension: an Efficacy and/or Cost or Just a Men's Issue?. 2019 , 21, 22	11
70	Treatment of Resistant and Refractory Hypertension. 2019 , 124, 1061-1070	50
69	Management of Chronic Hypertension Following Intracerebral Hemorrhage. 2019 , 42, 148-164	5
68	Adrenal Tissue-Specific Deletion of TASK Channels Causes Aldosterone-Driven Angiotensin II-Independent Hypertension. 2019 , 73, 407-414	7
67	Shake Rattle & Roll - Design and rationale for a pragmatic trial to improve blood pressure control among blacks with persistent hypertension. 2019 , 76, 85-92	7

66	Prevalence and characteristics of apparent treatment-resistant hypertension in older people in China: a cross-sectional study. 2019 , 41, 753-758	1
65	Long-term blood pressure outcomes of patients with adrenal venous sampling-proven unilateral primary aldosteronism. 2020 , 34, 440-447	6
64	Use of Diuretics in Chronic Kidney Disease Patients. 2020 , 1053-1070	1
63	Double-Blind Randomized Phase 3 Study Comparing Esaxerenone (CS-3150) and Eplerenone in Patients With Essential Hypertension (ESAX-HTN Study). 2020 , 75, 51-58	43
62	Special Article - The management of resistant hypertension: A 2020 update. 2020 , 63, 662-670	2
61	Management of primary aldosteronism and mineralocorticoid receptor-associated hypertension. 2020 , 43, 744-753	5
60	Retrospective cohort study to characterise the blood pressure response to spironolactone in patients with apparent therapy-resistant hypertension using electronic medical record data. 2020 , 10, e033100	1
59	Clinical characteristics of concurrent primary aldosteronism and renal artery stenosis: A retrospective case-control study. 2021 , 43, 7-12	1
58	Efficacy and safety of esaxerenone (CS-3150), a newly available nonsteroidal mineralocorticoid receptor blocker, in hypertensive patients with primary aldosteronism. 2021 , 44, 464-472	9
57	Management of hyperkalemia during treatment with mineralocorticoid receptor blockers: findings from esaxerenone. 2021 , 44, 371-385	6
56	New drug targets for hypertension: A literature review. 2021 , 1867, 166037	7
55	Aldosterone sensitivity: an opportunity to explore the pathogenesis of hypertension. 2021 , 320, F325-F335	0
54	Diuretic-induced hypokalaemia: an updated review. 2021 ,	1
53	Association of Apparent Treatment-Resistant Hypertension With Differential Risk of End-Stage Kidney Disease Across Racial Groups in the Million Veteran Program. 2021 , 78, 376-386	1
52	Spironolactone Reduces Aortic Stiffness in Patients With Resistant Hypertension Independent of Blood Pressure Change. 2021 , 10, e019434	4
51	Hormonal Systems. <i>Updates in Hypertension and Cardiovascular Protection</i> , 2018 , 81-106	0.1 1
50	Aldosterone and its Cardiovascular Effects. 2009 , 349-359	1
49	Recent Advances in Mineralocorticoid Receptor Antagonists. 2011 , 89-102	4

48	Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2004). 2006 , 29 Suppl, S1-105	190
47	Blood Pressure Control during Hospitalization at the Department of Medicine. 001-004	1
46	Use of spironolactone in the treatment of resistant arterial hypertension. 2011 , 53, 343-347	4
45	Management of resistant hypertension. 2011 , 53, 423-428	1
44	Overview of resistant hypertension: A glimpse of the cardiologist's current standpoint. 2012 , 4, 275-83	1
43	Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT)--study protocol. 2011 , 155, 143-8	8
42	The effect of spironolactone in patients with resistant arterial hypertension in relation to baseline blood pressure and secondary causes of hypertension. 2013 , 157, 50-5	7
41	Effect of spironolactone in patients with resistant arterial hypertension in relation to age and sex: insights from the aspirant trial. 2014 , 158, 384-90	3
40	Population Care Management and Team-Based Approach to Reduce Racial Disparities among African Americans/Blacks with Hypertension. 2016 , 20, 53-9	26
39	Resistant Hypertension. 2005 , 616-623	
38	Initial Evaluation and Follow-Up Assessment. 2005 , 295-304	
37	Intracrine mechanisms in hypertension. 2006 , 112-123	
36	Resistant Hypertension. 2007 , 498-511	
35	Pharmacologic Treatment of Hypertension. 2007 , 578-599	
34	Resistant Hypertension. 2007 , 658-665	
33	Aldosterone blockade, a new strategy in the treatment of resistant hypertension. 2008 , 14, 203-210	1
32	Pharmacotherapy for Hormone Excess in Adrenocortical Carcinoma. 2009 , 383-402	
31	Case 21. Hypertension. 2009 ,	

30 5.?????????????????????????????????. **2009**, 40, 51S-52S

29 Primary Mineralocorticoid Excess Syndromes and Hypertension. **2010**, 1959-1979

28 Diuretics. **2011**, 1879-1916

27 Rational combination therapy in resistant arterial hypertension. **2011**, 17, 384-390

26 Primary aldosteronism and resistant arterial hypertension. **2012**, 18, 514-521 2

25 Treatment of Resistant Hypertension. Which Additional Antihypertensive Drugs?. **2013**, 115-126 2

24 Follow-up of Patients with Resistant Hypertension. **2013**, 155-169

23 Aldosterone and Cardiovascular Diseases. **2014**, 155-196

22 Problem of resistant arterial hypertension in the family doctor practice. **2015**, 2015, 26-31

21 Optimization of Antihypertensive Drug Treatment in Resistant Hypertension. *Updates in Hypertension and Cardiovascular Protection*, **2016**, 139-149 0.1

20 Treatment of Resistant Hypertension. *Updates in Hypertension and Cardiovascular Protection*, **2018**, 639-652

19 Hypertension and Diabetes. **2018**, 109-130

18 Hypertension and Diabetes. **2019**, 1-22

17 Hypertension and Diabetes. **2020**, 109-130

16 Management of Hypertension. **2006**, 93-112

15 Obstructive sleep apnea is more severe in men but not women with refractory hypertension compared with controlled resistant hypertension. **2021**, 39, 286-291 1

14 Resistant hypertension: current status, future challenges. **2014**, 5, S21-4 2

13 Management of Resistant Hypertension: Do Not Give Up on Medication. **2014**, 13, 57-63 4

12	Clinical efficacy of spironolactone for resistant hypertension: a meta analysis from randomized controlled clinical trials. 2015 , 8, 7270-8		15
11	PURLs: Resistant hypertension? Time to consider this fourth-line drug. 2016 , 65, 266-8		
10	Refractory versus resistant hypertension: Novel distinctive phenotypes. 2017 , 3,		11
9	Low Dose Spironolactone Monotherapy in the Management of Stage I Essential Hypertension: A Pilot Randomized, Double-Blind, Placebo-Controlled Trial. 2018 , 34, 59-65		12
8	Obstructive sleep apnea, hypertension, resistant hypertension and cardiovascular disease. 2020 , 4, 67-76		2
7	Thiazide diuretics alone or in combination with a potassium-sparing diuretic on blood pressure-lowering in patients with primary hypertension: protocol for a systematic review and network meta-analysis.. <i>Systematic Reviews</i> , 2022 , 11, 23	3	1
6	Resistant Hypertension: Recognition and Treatment. <i>Updates in Hypertension and Cardiovascular Protection</i> , 2022 , 351-366		0.1
5	Relationship Between Risks for Obstructive Sleep Apnea, Resistant Hypertension, and Aldosterone Among African American Adults in the Jackson Heart Study.		
4	Chlorthalidone for Resistant Hypertension in Advanced Chronic Kidney Disease. 2022 , 146, 718-720		0
3	Mechanisms of mineralocorticoid receptor-associated hypertension in diabetes mellitus: the role of O-GlcNAc modification.		0
2	Should we CLICK on Chlorthalidone for treatment resistant hypertension in chronic kidney disease?.		0
1	Antihypertensive effects of pentacyclic triterpenoid from <i>Convolvulus pluricaulis</i> and its plausible mechanism of action hypothesizing its selectivity targeting Mineralocorticoid receptor of RAAS.. 2023 , 3, 100408		0